April 29, 2016

DIVA Ventures welcomes Novozymes and DSM as co-founders - A partnership to scale up impact ventures

The EVPA member DIVA Ventures has welcomed as co-founders biotechnology company Novozymes and global science based Royal DSM. The announcement was made last week at the United Nations HQ in New York.


As co-founders of DIVA, Novozymes and DSM will provide seed funding to ensure the continued development of the DIVA organisation and coalition, while exploring potential impact venture opportunities for co-development.

“We imagine a future where the world’s greatest challenges are met with business solutions from the world’s leading corporations, deployed at scale and effectively leveraging commercial capital,” says Morten Møller Holst, Managing Director of DIVA Ventures L3C, and continues: “Our purpose is to address the SDGs through corporate impact venturing, and help make this a mainstream activity of large corporations – and we are delighted to have pioneers like Novozymes and DSM as our first corporate partners on this journey.”

In the near term, the DIVA team will continue to recruit corporate partners, mature the DIVA organisation, raise additional grant philanthropic funding, and begin to pilot the first corporate impact venture projects.

Novozymes and Royal DSM join existing partners, the World Business Council for Sustainable Development (WBCSD) and Pillsbury Winthrop Shaw Pittman LLP.

To know more, check DIVA Ventures’ press release here or contact Morten Møller Holst, Managing Director of DIVA.

Search the website

Use the following form to search our website